Is stem cell therapy for Complex Regional Pain Syndrome FDA-approved?
No regenerative medicine therapy is FDA-approved for CRPS or chronic pain. An IND-authorised study, registry listing or ATMP classification is not product approval. In Europe, a trial authorisation is distinct from EMA marketing authorisation. Patients should verify the exact product, sponsor, registry identifier, competent authority and ethics approval.
How stem cells are studied for Complex Regional Pain Syndrome
Complex regional pain syndrome (CRPS) is a chronic pain condition that may follow injury or surgery and can involve sensory, autonomic, motor and trophic changes in a limb. Management is individualised and commonly includes rehabilitation, pain treatment and psychological support, with specialist interventions in selected cases. Mesenchymal stromal cells (MSCs) and other cell approaches are experimental; proposed inflammatory or neural mechanisms have not established clinical benefit. The registry table on this page lists relevant studies and their current recruitment status.
Am I a candidate? → · Complex Regional Pain Syndrome: full overview → · Complex Regional Pain Syndrome cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.